The Role of Nrf2-Mediated Pathway in Cardiac Remodeling and Heart Failure

Oxidative Medicine and Cellular Longevity - Tập 2014 - Trang 1-16 - 2014
Shanshan Zhou1, Wanqing Sun1, Zhiguo Zhang1, Yang Zheng1
1The Cardiovascular Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China

Tóm tắt

Heart failure (HF) is frequently the consequence of sustained, abnormal neurohormonal, and mechanical stress and remains a leading cause of death worldwide. The key pathophysiological process leading to HF is cardiac remodeling, a term referring to maladaptation to cardiac stress at the molecular, cellular, tissue, and organ levels. HF and many of the conditions that predispose one to HF are associated with oxidative stress. Increased generation of reactive oxygen species (ROS) in the heart can directly lead to increased necrosis and apoptosis of cardiomyocytes which subsequently induce cardiac remodeling and dysfunction. Nuclear factor-erythroid-2- (NF-E2-) related factor 2 (Nrf2) is a transcription factor that controls the basal and inducible expression of a battery of antioxidant genes and other cytoprotective phase II detoxifying enzymes that are ubiquitously expressed in the cardiovascular system. Emerging evidence has revealed that Nrf2 and its target genes are critical regulators of cardiovascular homeostasis via the suppression of oxidative stress, which is the key player in the development and progression of HF. The purpose of this review is to summarize evidence that activation of Nrf2 enhances endogenous antioxidant defenses and counteracts oxidative stress-associated cardiac remodeling and HF.

Từ khóa


Tài liệu tham khảo

10.1161/01.RES.0000248212.86638.e9

10.1016/j.drudis.2006.04.003

10.1161/01.CIR.0000048966.26216.4C

10.1161/01.ATV.0000150649.39934.13

10.1016/j.cardiores.2006.03.016

10.1161/01.HYP.0000254415.31362.a7

10.1161/ATVBAHA.109.189480

10.1016/j.freeradbiomed.2011.01.003

10.1016/j.freeradbiomed.2008.03.020

10.1098/rspb.2008.1791

10.1016/j.tibs.2010.07.007

10.1155/2011/293769

10.1016/j.freeradbiomed.2009.12.022

10.1161/01.CIR.76.2.458

10.1016/0022-2828(91)90133-7

10.1161/01.RES.87.12.1172

10.1016/j.mam.2011.10.006

10.1016/j.cardfail.2011.11.003

10.1155/2013/919313

10.1016/j.febslet.2005.04.058

10.1007/s12012-008-9016-0

10.1152/ajpheart.00796.2012

10.1007/s11010-012-1458-9

10.1161/hh1001.091521

10.1161/01.CIR.0000135475.35758.23

10.1161/HYPERTENSIONAHA.107.098186

10.1152/ajpheart.00427.2006

10.1007/s00395-013-0359-8

10.3109/15376516.2012.666650

10.1111/j.1540-8167.1999.tb00214.x

10.1161/hc1002.105185

10.2337/diabetes.51.6.1938

10.3892/ijmm.2013.1475

10.1007/s11010-008-9803-8

10.1096/fj.05-4642fje

10.1089/ars.2007.1474

10.1089/152308603770380034

10.1016/j.pharmthera.2014.01.003

10.1016/j.cardiores.2005.04.012

10.1016/S0928-4680(00)00053-5

10.1016/j.advenzreg.2006.01.007

10.1089/ars.2006.8.88

10.1146/annurev.pharmtox.46.120604.141046

10.1074/jbc.274.10.6443

10.1093/nar/26.2.512

10.1074/jbc.272.26.16490

10.1101/gad.13.1.76

10.1128/MCB.24.16.7130-7139.2004

10.1128/MCB.01704-07

10.1006/bbrc.1997.6943

10.1155/2013/104308

2000, American Journal of Physiology: Lung Cellular and Molecular Physiology, 279, L1029

10.1016/j.freeradbiomed.2005.03.010

10.1016/j.freeradbiomed.2007.12.007

10.1016/j.mam.2008.08.006

10.1161/01.CIR.0000109701.77059.E9

10.1016/j.cardiores.2005.06.021

10.1038/labinvest.2009.39

10.1017/S1462399411001815

10.1016/j.freeradbiomed.2011.05.004

10.1080/08037050802029954

2000, The American Journal of Physiology—Heart and Circulatory Physiology, 278, H412, 10.1152/ajpheart.2000.278.2.H412

10.1093/cvr/cvt225

2013, Free Radical Biology & Medicine, 65, 897, 10.1016/j.freeradbiomed.2013.08.179

2013, The American Journal of Physiology—Heart and Circulatory Physiology, 305, H1658, 10.1152/ajpheart.00349.2013

10.1371/journal.pone.0044899

2014, Molecular Pharmacology, 85, 682, 10.1124/mol.113.090092

10.1016/j.cardfail.2009.02.003

10.1161/HYPERTENSIONAHA.107.102566

10.1002/jcp.20723

10.1159/000331710

10.1161/CIRCRESAHA.108.193318

10.1038/ajh.2008.242

10.1152/japplphysiol.01392.2010

10.1093/cvr/cvp032

10.1016/j.cardiores.2003.12.023

10.2174/138920112798868782

10.1093/cvr/cvn333

10.1371/journal.pone.0058371

10.1016/j.cmet.2012.01.017

10.1161/HYPERTENSIONAHA.113.01639

2007, Vascular Health and Risk Management, 3, 629

10.1016/j.freeradbiomed.2007.04.025

10.1002/path.1106

10.1006/jmcc.1999.0995

10.1161/CIRCULATIONAHA.109.905471

2002, American Journal of Physiology: Heart and Circulatory Physiology, 283, H688

10.1161/01.CIR.103.12.1695

10.1161/hh1401.093314

10.1161/hc0502.103363

10.1152/ajpheart.00741.2006

10.1161/01.RES.72.6.1293

10.1161/01.CIR.96.6.1745

10.1006/jmcc.1996.0165

1997, Circulation, 96, II216

10.1016/j.freeradbiomed.2008.06.021

10.1385/CT:1:3:181

10.2174/09298673113209990154

10.1038/35008121

10.2337/diabetes.49.11.1939

10.2174/092986707781389646

10.1016/j.phrs.2009.11.009

10.1016/j.yjmcc.2013.01.008

10.1093/abbs/gmq012

10.1016/j.bcp.2012.10.025

10.1152/ajpheart.00650.2012

10.1111/j.1582-4934.2010.01140.x

10.1007/s10557-012-6415-z

10.1161/CIRCRESAHA.109.199919

10.1016/j.yjmcc.2010.05.011

10.3390/ijms14022684

10.1242/dmm.011528

10.1016/j.jacc.2006.02.075

10.1016/j.ejphar.2006.06.033

10.1016/j.yjmcc.2008.10.007

10.2337/db10-1164

10.1155/2012/216512

10.1007/s00439-002-0769-4

10.1371/journal.pone.0075927

10.2337/diabetes.54.3.778

10.1562/2005-10-20-RN-723

10.1248/bpb.29.1042

10.1053/j.seminoncol.2013.01.008

10.1016/j.bbrc.2007.05.027

10.1007/s00204-011-0700-7

10.7326/0003-4819-105-1-67

10.1007/s00204-010-0615-8

2013, Toxicology and Applied Pharmacology, 274, 107

10.1006/bbrc.1998.9363

10.1146/annurev.pharmtox.47.120505.105144

10.1124/jpet.112.1983583

10.1042/BJ20021619

10.1038/sj.bjp.0701877

10.1111/j.1582-4934.2011.01281.x

10.1089/ars.2006.8.99

2000, Drug Metabolism and Drug Interactions, 17, 3

10.1016/j.jnutbio.2013.01.008

10.1016/j.freeradbiomed.2011.04.022

10.1073/pnas.1002178107

10.1093/cvr/cvp107

10.1016/j.thromres.2008.01.011

10.1155/2013/306073

10.1002/jbt.21417

10.1074/jbc.M112.385542

10.1093/cvr/cvr072

10.2337/diabetes.54.3.803

10.3325/cmj.2013.54.171

10.1096/fj.05-5211com

10.1016/j.cellbi.2008.07.010

10.1016/j.yjmcc.2006.07.023

10.1016/j.jacc.2005.05.079

10.1016/j.tice.2010.04.004

10.1186/1423-0127-17-80

10.1016/0891-5849(92)90075-R

10.1097/00005344-199104000-00023

10.1093/cvr/26.4.347

10.1016/0891-5849(92)90018-C

10.1161/CIRCIMAGING.112.000320

10.1002/term.523